CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

40-009

ADMINISTRATIVE DOCUMENTS

ANDA APPROVAL SUMMARY

ANDA: 40-009 DRUG PRODUCT: Isosorbide Dinitrate Extended Release Tablets USP

FIRM: Inwood DOSAGE FORM: Tablet STRENGTHS: 40 mg
909 Third Avenue
New York, New York 10022-4731

CGMP STATEMENT/EIR UPDATE STATUS:

CGMP statement (p. 234) in original submission. Original submission predates Paragraph 306(k) certification.

EIR acceptable for drug product manufacturer and drug substance manufacturer, 5/12/98.

Facilities included:

Manufacturing, testing, packaging, labeling, and stability testing:

Inwood Laboratories, Inc.
300 Prospect Street
Inwood, New York 11696

Drug Substance Manufacturer:

BIO STUDY:

Bioequivalence studies conducted on the 40 mg tablets, Lot #88125D, batch size tablets, Lot #94020A, batch size tablets, and Lot #96064E, batch size tablets, were found acceptable by the Division of Bioequivalence per A. Jackson, 11/25/98.

In-vitro dissolution study for 40 mg tablets was found acceptable. Firm's release specifications consistent with those proposed by the Office of Bioequivalence.

VALIDATION - (DESCRIPTION OF DOSAGE FORM SAME AS FIRM'S):

Drug substance and drug product are compendial.

STABILITY - ARE CONTAINERS USED IN STUDY IDENTICAL TO THOSE IN CONTAINER SECTION?:

Stability for the following included:

Lot #	Batch Size	Sample	Test Conditions
88125D		100's	40°C/75% RH/3 months
		1000's	25° - 30°C/24 months

Container/Closure system:

100's in 100 cc white bottle, 38 mm plastic/metal child resistant cap, innerseal/liner, rayon coil.

1000's in 750 cc white bottle, 53 mm metal screw cap, innerseal/liner, rayon coil.

All container/closure systems are as described in the Container/Closure section.

Expiration date: 24 months based on room temperature stability data.

LABELING:

Description in package insert satisfactory for molecular structure, molecular formula, formula weight, inactive ingredients, product description and package size.

Professional labeling - satisfactory, A. Vezza, 1/6/98.

STERILIZATION VALIDATION (IF APPLICABLE): N/A

SIZE OF BIO BATCH (FIRM'S SOURCE OF NDS OK?):

Bio batch: 40 mg product, Lot #88125D, batch size tablets, stability data included, Lot #94020A, batch size tablets, Lot #96064E, batch size tablets.

Diluted Isosorbide Dinitrate, satisfactory, G.J. Smith, 11/3/97, no amendments since then.

SIZE OF STABILITY BATCHES - (IF DIFFERENT FROM BIO BATCH, WERE THEY MANUFACTURED VIA THE SAME PROCESS?):

See above.

PROPOSED PRODUCTION BATCH - MANUFACTURING PROCESS THE SAME AS BIO/STABILITY?:

An executed batch record for the 40 mg x batch (bioequivalence/stability batch) included. A blank batch record was submitted in the application for granulation and compression for . All scale-ups consistent with current Office policy. Proposed manufacturing processes are the same as the bio/stability batches.

CHEMIST: Glen J. Smith DATE: 11.27.98

SUPERVISOR: Ubrani Venkataram DATE: 12.8.98

U.V. Venkataram 12/11/98.

pf

M E M O R A N D U M: RECORD OF TELEPHONE CONVERSATION/MEETING

DATE: 25 November 1998

SUBJECT: ANDA 40-009, Isosorbide Dinitrate

INITIATED BY: Glen Jon Smith, OGD

ATTENDANCE - FDA: Glen Jon Smith GJS — 11/25/98

FIRM: Foma Rashkovsky

RECORD: I requested that the firm commit to an editorial change in the dissolution specifications in the first annual report for the application. The change requested was to indicate the dissolution medium and pH for each time period in the specifications to be consistent with the current procedure. The change should be considered a Telephone Amendment. The firm agreed to fax the commitment, followed by hard copy.